Since the GCGR agonists have emerged as potential therapeutic options for managing obesity, diabetes and other metabolic disorders, one intriguing development in this field is the discovery of unimolecular dual agonists that simultaneously activate both the GLP1R and the GCGR. This evidence concerns the gene GCGR and obesity due to melanocortin 4 receptor deficiency.